Blueprint Medicines (BPMC) News Today $99.16 -2.67 (-2.62%) Closing price 04:00 PM EasternExtended Trading$100.00 +0.84 (+0.85%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Blueprint Medicines Is A Fast-Growing Small-Cap StockMay 7 at 12:02 AM | theglobeandmail.comAvidity Partners Management LP Sells 138,400 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Avidity Partners Management LP trimmed its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 43.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 176,600 shares of the biotechnology company's stockMay 6 at 7:39 AM | marketbeat.comAlgert Global LLC Raises Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Algert Global LLC grew its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 21.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 112,172 shares of the biotechnology company's stock after purchasing an additionMay 6 at 5:41 AM | marketbeat.comThe Manufacturers Life Insurance Company Acquires 26,488 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)The Manufacturers Life Insurance Company increased its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 17.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 176,484 shares of the biMay 6 at 4:39 AM | marketbeat.comAlkeon Capital Management LLC Acquires 81,700 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Alkeon Capital Management LLC boosted its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 800,628 shares of the biotecMay 5 at 7:44 AM | marketbeat.comPDT Partners LLC Purchases Shares of 3,098 Blueprint Medicines Co. (NASDAQ:BPMC)PDT Partners LLC acquired a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,098 shares of the biotechnology company's stock, valued at apMay 5 at 5:11 AM | marketbeat.comBlueprint Medicines' (BPMC) Buy Rating Reiterated at HC WainwrightMay 5 at 2:32 AM | americanbankingnews.comBlueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their EstimatesMay 4 at 1:13 PM | finance.yahoo.comBlueprint Medicines (NASDAQ:BPMC) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday.May 4 at 8:30 AM | marketbeat.comAlly Bridge Group NY LLC Has $4.88 Million Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Ally Bridge Group NY LLC lessened its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 47.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 55,892 shares of the biotechnology company's stock after selling 50,18May 4 at 7:45 AM | marketbeat.comHsbc Holdings PLC Cuts Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Hsbc Holdings PLC lowered its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 37.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,019 shares of the biotechnology compMay 4 at 4:10 AM | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Rating Increased to Hold at StockNews.comMay 4 at 3:41 AM | americanbankingnews.comBlueprint Medicines Corp.May 2, 2025 | barrons.comBlueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...May 2, 2025 | finance.yahoo.comBlueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comBlueprint Medicines Corporation 2025 Q1 - Results - Earnings Call PresentationMay 1, 2025 | seekingalpha.comEmerald Mutual Fund Advisers Trust Sells 19,562 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Emerald Mutual Fund Advisers Trust decreased its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 268,978 shares of the biotechnologMay 1, 2025 | marketbeat.comBlueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceMay 1, 2025 | prnewswire.comSusquehanna Fundamental Investments LLC Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)Susquehanna Fundamental Investments LLC purchased a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 56,245 shareMay 1, 2025 | marketbeat.comWhat Analysts Are Saying About Blueprint Medicines StockApril 30, 2025 | nasdaq.comNeedham & Company LLC Has Lowered Expectations for Blueprint Medicines (NASDAQ:BPMC) Stock PriceNeedham & Company LLC cut their price objective on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research report on Monday.April 30, 2025 | marketbeat.comAquatic Capital Management LLC Acquires 5,002 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Aquatic Capital Management LLC lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,602 shares of the biotechnology company's sApril 30, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Bought by Voya Investment Management LLCVoya Investment Management LLC boosted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 205,391 shares of tApril 30, 2025 | marketbeat.comTower Research Capital LLC TRC Buys 6,541 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Tower Research Capital LLC TRC lifted its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 903.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,265 shares of the biotechnology company'April 30, 2025 | marketbeat.comNeedham & Company LLC Lowers Blueprint Medicines (NASDAQ:BPMC) Price Target to $130.00April 30, 2025 | americanbankingnews.comLord Abbett & CO. LLC Trims Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Lord Abbett & CO. LLC decreased its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 71.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 335,043 shares of the biotechnology company's stock after selling 843,April 29, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Sells 51,665 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)T. Rowe Price Investment Management Inc. reduced its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 6.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 697,027 shares of the biotechnology company's stApril 28, 2025 | marketbeat.comEnvestnet Asset Management Inc. Buys 3,723 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Envestnet Asset Management Inc. lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 13.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 32,115 shares of the biotechnology company's stock after purchasing an additionApril 28, 2025 | marketbeat.comOberweis Asset Management Inc. Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)Oberweis Asset Management Inc. acquired a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 75,000 shares of the biotechnology company's stock, valued aApril 27, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Raises Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)Price T Rowe Associates Inc. MD lifted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 5.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,679,089 shares of the biotechnology company's stockApril 27, 2025 | marketbeat.comCanada Pension Plan Investment Board Takes $1.73 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)Canada Pension Plan Investment Board acquired a new stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,800 shares of the biApril 26, 2025 | marketbeat.comCerity Partners LLC Purchases New Position in Blueprint Medicines Co. (NASDAQ:BPMC)Cerity Partners LLC purchased a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,298 shares of the biotechnology company's stock,April 26, 2025 | marketbeat.comBlueprint Medicines (BPMC) to Release Earnings on ThursdayBlueprint Medicines (NASDAQ:BPMC) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-blueprint-medicines-co-stock/)April 26, 2025 | marketbeat.comBlueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025April 25, 2025 | prnewswire.comHood River Capital Management LLC Acquires 207,496 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Hood River Capital Management LLC grew its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 30.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 879,932 shares of the biotechnology company's stock after buying an additioApril 25, 2025 | marketbeat.comGuggenheim Capital LLC Sells 3,725 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Guggenheim Capital LLC reduced its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 22.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,139 shares of the biotechnology company's stock afteApril 25, 2025 | marketbeat.comWells Fargo & Company MN Cuts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Wells Fargo & Company MN decreased its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 38.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,732 shares of the biotecApril 25, 2025 | marketbeat.comDiadema Partners LP Acquires New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)Diadema Partners LP bought a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 64,193 shares of the biotechnology company's stock, valued at approximatelyApril 24, 2025 | marketbeat.comBlueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are BuyingApril 23, 2025 | msn.comAvoro Capital Advisors LLC Acquires New Shares in Blueprint Medicines Co. (NASDAQ:BPMC)Avoro Capital Advisors LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,185,000 shares of the biotechnologyApril 23, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) is Rock Springs Capital Management LP's 5th Largest PositionRock Springs Capital Management LP boosted its stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 42.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,096,899 shares of the biotechnology company's stock afApril 23, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Marshall Wace LLPMarshall Wace LLP trimmed its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 51.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 161,882 shares of the biotechnology company's stock after sellingApril 23, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Shares Purchased by Barclays PLCBarclays PLC grew its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 10.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 189,127 shares of the biotechnology cApril 22, 2025 | marketbeat.comAlpha DNA Investment Management LLC Buys New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Alpha DNA Investment Management LLC purchased a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,098 shares of the bioteApril 21, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Stake in Blueprint Medicines Co. (NASDAQ:BPMC)Raymond James Financial Inc. bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 241,966 shares of the biotechnology company's stock, valued at approxiApril 21, 2025 | marketbeat.comWedbush Forecasts Reduced Earnings for Blueprint MedicinesBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Wedbush cut their Q1 2025 earnings per share (EPS) estimates for Blueprint Medicines in a report issued on Wednesday, April 16th. Wedbush analyst D. Nierengarten now expects that the biotechnology company will post earnings per share of ($0.58April 20, 2025 | marketbeat.comResearch Analysts Issue Forecasts for BPMC Q3 EarningsBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at Wedbush issued their Q3 2026 EPS estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst D. Nierengarten expects that the biotechnApril 19, 2025 | marketbeat.comRenaissance Technologies LLC Lowers Position in Blueprint Medicines Co. (NASDAQ:BPMC)Renaissance Technologies LLC trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 27.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 126,300 shares of the biotechnology company'sApril 19, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Earns Outperform Rating from WedbushWedbush restated an "outperform" rating and issued a $128.00 target price on shares of Blueprint Medicines in a report on Wednesday.April 18, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Stock Position Raised by XTX Topco LtdXTX Topco Ltd lifted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 406.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,146 shares of the biotechnology company's stock after buying an additionalApril 18, 2025 | marketbeat.com Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Media Mentions By Week BPMC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.800.69▲Average Medical News Sentiment BPMC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼288▲BPMC Articles Average Week Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ONC News Today BNTX News Today SMMT News Today TEVA News Today ITCI News Today GMAB News Today RDY News Today MRNA News Today ASND News Today VTRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
